iRNA agents with biocleavable tethers
View Patent ↗The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
1. An iRNA agent comprising a first strand and optionally a second strand, wherein at least one subunit having a formula (I) is incorporated into at least one of the strands:
wherein:
X is N(CO)R 7 , NR 7 or CH 2 ;
Y is NR 8 , O, S, CR 9 R 10 , or absent;
Z is CR 11 R 12 or absent;
Each of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , OR b , (CH 2 ) n OR a , or (CH 2 ) n OR b , provided that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a or OR b and that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a , or (CH 2 ) n OR b ;
Each of R 5 , R 6 , R 11 , and R 12 is, independently, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with R 14 ;
R 7 is T-R d , in which T is a tether having the formula -(E′) s -Δ-(E″) t ; and R d H or a ligand,
wherein:
each of E′ and E″ is a linking group;
Δ is a hydrocarbon chain that optionally includes one or more linking groups, G;
each of s and t is, independently, 0 or 1; and
at least one of the E′, E″ or G linking groups is a cleavable disulfide (—SS—) group;
provided that one of s or t is 1, or Δ includes at least one G;
R 8 is C 1 -C 6 alkyl;
R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;
R 14 is NR c R 7 ;
R a is H or
R b is H or
Each of A and C is, independently, O or S;
B is OH, O − , or
R c is H or C 1 -C 6 alkyl; and
n is 1-4; provided that X is N(CO)R 7 or NR 7 ; or one of R 5 , R 6 , R 11 , and R 12 is C(O)NHR 7 ; or R 14 is present.
2. The agent of claim 1 , wherein at least one of the linking groups is cleaved at least about 100 times faster under conditions chosen to mimic intracellular media than under conditions chosen to mimic extracellular media.
3. The agent of claim 1 , wherein at least one of the linking groups is cleaved at least about 50 times faster under conditions chosen to mimic intracellular media than under conditions chosen to mimic extracellular media.
4. The agent of claim 1 , wherein at least one of the linking groups is cleaved at least about 10 times faster under conditions chosen to mimic intracellular media than under conditions chosen to mimic extracellular media.
5. The agent of claim 1 , wherein each of E′, E″, and G is, independently,
—NR k C(O)—, —C(O)NR k —, —OC(O)NR k —, —NR k C(O)O, —O—, —S—, —SS—, —S(O)—, —S(O 2 )—,
—NR k C(O)NR k —, —NR k C(S)NR k —, —C(O)O—, —OC(O)—, —NR k C(S)—, —NR k C(S)O—,
—C(S)NR k —, —OC(S)NR k —, —NR k C(S)O—, —O—P(O)(OR k )—O—, —O—P(S)(OR k )—O—,
—O—P(S)(SR k )—O—, —S—P(O)(OR k )—O—, —O—P(O)(OR k )—S—, —S—P(O)(OR k )—S—,
—O—P(S)(OR k )—S—, —S—P(S)(OR k )—O—, —O—P(O)(R k )—O—, —O—P(S)(R k )—O—,
—S—P(O)(R k )—O—, —S—P(S)(R k )—O—, —S—P(O)(R k )—S—, —O—P(S)(R k )—S—, —C(O)—, —NR k —
—R k C═NNR k —, —NHCHR k′ C(O)NHCHR k″ C(O)—, or —NHCHR k′ NHC(O)CHR k″ C(O)—;
wherein
R k at each occurrence is, independently, C1-C20 alkyl, C1-C20 haloalkyl, C6-C10 aryl, C7-C12 aralkyl; and
each of R k′ and R k″ is, independently of one another, an amino acid sidechain.
6. The agent of claim 5 , wherein at least one G is —SS—, —C(O)O—, —OC(O)—,
—R k C═NNR k —, —NHCHR k′ C(O)NHCHR k″ C(O)—, or —NHCHR k′ NHC(O)CHR k″ C(O)—.
7. The agent of claim 1 , wherein R d is a lipophilic moiety; a folic acid radical; a steroid radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; or a vitamin K radical.
8. The iRNA agent of claim 1 , wherein the at least one subunit has a formula (I′):
wherein:
X is N(CO)R 7 , or NR 7 ;
Each of R′, R 3 , and R 9 is, independently, H, OH, OR a , OR b , CH 2 OR a , or CH 2 OR b , provided that at least one of R′, R 3 , and R 9 is OH, OR a , or OR b and that at least one of R′, R 3 , and R 9 is CH 2 OR a , or CH 2 OR b ;
R 7 is T-R d , in which T is a tether having the formula -(E′) s —Δ—(E″) t ; and R d is H or a ligand,
wherein:
each of E′ and E″ is a linking group;
Δ is a hydrocarbon chain that optionally includes one or more linking groups, G;
each of s and t is, independently, 0 or 1; and
at least one of the E′, E″ or G linking groups is a cleavable disulfide (—SS—) group;
provided that one of s or t is 1, or A eincludes at least one G;
R a is H or
R b is H or
each of A and C is, independently, O or S; and
B is OH, O − , or
9. The iRNA agent of claim 8 , wherein at least one of the linking groups is cleaved at least about 100 times faster under conditions chosen to mimic intracellular media than under conditions chosen to mimic extracellular media.
10. The iRNA agent of claim 8 , wherein at least one of the linking groups is cleaved at least about 50 times faster under conditions chosen to mimic intracellular media than under conditions chosen to mimic extracellular media.
11. The iRNA agent of claim 8 , wherein at least one of the linking groups is cleaved at least about 10 times faster under conditions chosen to mimic intracellular media than under conditions chosen to mimic extracellular media.
12. The iRNA agent of claim 8 , wherein each of E′, E″, and G is, independently, —NR k C(O)—, —C(O)NR k —, —OC(O)NR k —, —NR k C(O)O, —O—, —S—, —SS—, —S(O)—, —S(O 2 )—, —NR k C(O)NR k —, —NR k C(S)NR k —, —C(O)O—, —OC(O)—, —NR k C(S)—, —NR k C(S)O—,
—C(S)NR k —, —OC(S)NR k —, —NR k C(S)O—, —O—P(O)(OR k )—O—, —O—P(S)(OR k )—O—,
—O—P(S)(SR k )—O—, —S—P(O)(OR k )—O—, —O—P(O)(OR k )—S—, —S—P(O)(OR k )—S—,
—O—P(S)(OR k )—S—, —S—P(S)(OR k )—O—, —O—P(O)(R k )—O—, —O—P(S)(R k )—O—,
—S—P(O)(R k )—O—, —S—P(S)(R k )—O—, —S—P(O)(R k )—S—, —O—P(S)(R k )—S—, —C(O)—, —NR k —
—R k C═NNR k —, —NHCHR k′ C(O)NHCHR k″ C(O)—, or —NHCHR k′ NHC(O)CHR k″ C(O)—;
wherein
R k at each occurrence is, independently, C1-C20 alkyl, C1-C20 haloalkyl, C6-C10 aryl, C7-C12 aralkyl; and
each of R k′ and R k″ is, independently of one another, an amino acid sidechain.
13. The iRNA agent of claim 8 , wherein at least one G is —SS—, —C(O)O—, —OC(O)—, —R k C=NNR k —, —NHCHR k′ C(O)NHCHR k″ C(O)—, or —NHCHR k′ NHC(O)CHR k″ C(O)—.
14. The iRNA agent of claim 8 , wherein R d is a lipophilic moiety; a folic acid radical; a steroid radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; or a vitamin K radical.
15. The iRNA agent of claim 14 , wherein the R d steroid radical is a cholesterol radical.
16. The iRNA agent of claim 7 , wherein the R d steroid radical is a cholesterol radical.
17. The iRNA agent of claim 1 , wherein the iRNA agent is a single-stranded iRNA agent.
18. The iRNA agent of claim 17 , wherein the single-stranded iRNA agent is an siRNA agent.
19. The iRNA agent of claim 1 , wherein the iRNA agent is a double-stranded iRNA agent comprising a first strand and a second strand.
20. The iRNA agent of claim 19 , wherein the double-stranded iRNA is an siRNA agent.